Hernandez, A, Munoz-Marmol, AM, Esteve-Codina, A, Alameda, F, Carrato, C, Pineda, E, Arpi-Llucia, O, Martinez-Garcia, M, Mallo, M, Gut, M, del Barco, S, Gallego, O, Dabad, M, Mesia, C, Bellosillo, B, Domenech, M, Vidal, N, Aldecoa, I, de la Iglesia, N, Balana, C. In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-18608-8. PMID:36002559. IF:4.600(Q2/4D).

Caravaca-Fontan, F, Rivero, M, Cavero, T, Diaz-Encarnacion, M, Cabello, V, Ariceta, G, Quintana, LF, Marco, H, Barros, X, Ramos, N, Rodriguez-Mendiola, N, Cruz, S, Fernandez-Juarez, G, Rodriguez, A, de Jose, AP, Rabasco, C, Rodado, R, Fernandez, L, Perez-Gomez, V, Avila, A, Bravo, L, Espinosa, N, Allende, N, de la Nieta, MDS, Rodriguez, E, Olea, T, Melgosa, M, Huerta, A, Miquel, R, Mon, C, Fraga, G, de Lorenzo, A, Draibe, J, Gonzalez, F, Shabaka, A, Lopez-Rubio, ME, Fenollosa, MA, Martin-Penagos, L, Da Silva, I, Titos, JA, de Cordoba, SR, de Jorge, EG, Praga, M. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy. Clinical Kidney Journal. 2022; 15(9)DOI:10.1093/ckj/sfac108. PMID:36003665. IF:4.600(Q1/2D).

Jorda, P, Bosman, LP, Gasperetti, A, Mazzanti, A, Gourraud, JB, Davies, B, Frederiksen, TC, Weidmann, ZM, Di Marco, A, Roberts, JD, MacIntyre, C, Seifer, C, Deliniere, A, Alqarawi, W, Kukavica, D, Minois, D, Trancuccio, A, Arnaud, M, Targetti, M, Martino, A, Oliviero, G, Pipilas, DC, Carbucicchio, C, Compagnucci, P, Dello Russo, A, Olivotto, I, Calo, L, Lubitz, SA, Cutler, MJ, Chevalier, P, Arbelo, E, Priori, SG, Healey, JS, Calkins, H, Casella, M, Jensen, HK, Tondo, C, Tadros, R, James, CA, Krahn, AD, Cadrin-Tourigny, J. Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. EUROPEAN HEART JOURNAL. 2022; 43(32)DOI:10.1093/eurheartj/ehac289. PMID:35766180. IF:39.300(Q1/1D).

Zozaya, N, Abdalla, F, Zamora, SA, Filgueiras, JB, Carrillo, JMC, Sanchez, OD, Sinisterra, FD, Garcia-Ruiz, A, Pinto, PH, Manfredi, A, Olmos, JM, Luna, PMD, Puig, L, Ros, S, HIdalgo-Vega, A. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(6)DOI:10.1080/14737167.2022.2063842. PMID:35404728. IF:2.300(Q3/7D).

del Alcazar, E, Lopez-Ferrer, A, Martinez-Domenech, A, Julia, M, Ruiz-Villaverde, R, Fernandez-Freire, LR, Notario, J, Llamas-Velasco, M, Ferran, M, Carrascosa, JM. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(6)DOI:10.1080/09546634.2022.2079596. PMID:35593480. IF:2.900(Q2/4D).

Tonyali, S, Emiliani, E, Sener, TE, Pietropaolo, A, Ozsoy, M, Aboumarzouk, O, Somani, B, Kallidonis, P, Coninck, VMJD, Talso, M, Keller, EX, Macchione, N, Tailly, T. Definition of clinically insignificant residual fragments after percutaneous nephrolithotomy among urologists: a world-wide survey by EAU-YAU Endourology and Urolithiasis Working Group. Central European Journal Of Urology. 2022; 75(3)DOI:10.5173/ceju.2022.0115. PMID:36381161. IF:(Q/D).